The aim of the Schools for Health in Europe (SHE) network is to improve the health of children and young people in Europe, including reducing health inequalities, through a specific setting focus on schools. The network supports its members to further develop and sustain school health promotion by providing a European platform for school health promotion.For 2015-2017 4 specific objectives are formulated. By the end of 2017:• the functioning of national and regional health promoting school networks and the implementation of health promoting schools has been supported by sharing good practices, expertise and skills;• the professional development of SHE network members and other stakeholders has been supported by the delivery of the SHE support programme;• the visibility and access to evidence based information on school health promotion has increased by the delivery of publications and presentations;• the dissemination of school health promotion research findings and innovative research consortia has been promoted.Methods to achieve these objectives are: organising annual meetings and capacity building workshops. Maintaining SHE website, helpdesk, share information through newsletters and social media and by encouraging regional and cross-border cooperation. Developing online school twinning tool and the SHE online school manual. Developing an e-learning tool, organising a summer school, support publications and consultancy visits. Making SHE leaflets, factsheets, an online glossary and by representing the network at international conferences.The health of children and young people are and will be a key priority for the European Commission. The activities in the network relate directly to the first overall objective of the third programme of community action in the field of health (2014-2020) and thematic priorities 1.1 till 1.4 are high priority issues in school programmes and settings. The SHE network encourages a whole school approach to these priorities.


The European Organisation for Rare Diseases – EURORDIS – represents the voice of an estimated 30 million people living with a rare disease in the EU, and their families. The proposal submitted for Operating Grant FPA 2015-2017 is structured around four main objectives of utmost importance for the European rare disease patients’ community:
1. To consolidate the Rare Disease patients’ community and strengthen the RDs patients’ voice;
2. To actively engage rare disease patients’ representatives into the effective implementation and monitoring of relevant EU legislation / strategies and support their integration at national level;
3. To build capacities and empower rare disease patients advocates, members and volunteers;
4. To sustain human, financial and organisational resources.

EURORDIS achieves these objectives through the following activities: collecting data as well as gathering, disseminating and sharing information; support capacity-building to empower patients’ advocates; providing patients, families, carers, decision-makers and other stakeholders with relevant expertise to inform policy-making; generating EU added-value and support Member States efforts; promoting translational research towards therapeutic intervention for patients; serving as a relay of two-ways information flow between policy makers and rare disease patient groups; promoting access to high quality and safe healthcare services for rare disease patients throughout the EU.

Through these activities, EURORDIS will contribute to the implementation of the priorities of the Third Public Health Programme which are to complement, add value and support national policies and strategies implemented by Member States to improve health, reduce health inequalities, support health capacity-building, generate and disseminate health information, contribute to innovative, efficient and sustainable health systems, support cross border healthcare in order to facilitate access to better and safer healthcare.


The TB Europe Coalition (TBEC) is an advocacy network that brings together civil society representatives (individuals and organisations) from across the WHO European Region; in order to strengthen the role of civil society within the regional response to tuberculosis (TB), and to increase the political and financial commitment required to effectively control the epidemic in region. TBEC was formed by a group of TB advocates in 2009. They identified a need to capacitate and bring together civil society in order to address two major concerns: high-rates of drug resistance, coupled with low awareness among general populations and policy-makers about this problem. This was especially due to a scarcity of civil society stakeholders working on TB in the region, despite their important role within an effective response, with few capable of advocating for TB at national or regional level. TBEC addresses this by providing a coordinating body that brings together civil society stakeholders across the region, disseminates high-quality information and resources, promotes collaboration and best practice, and aims to build the advocacy capacity of civil society stakeholders working to control TB.


Within most European populations, smoking prevalence rates differ substantially according to people’s educational level, occupational class and income level. In the European countries, smoking inequalities are generally largest, and smoking is the largest single contributor to socio-economic inequalities in mortality. Significant inequalities in smoking are now emerging in all European countries, especially in the youngest generations. Tobacco products and secondhand smoke (SHS) kill, as documented in over 20 reports (eg: IARC, US Surgeon General). Exposure to SHS kills at least 79 000 people in the EU each year, incl. deaths from lung cancer, coronary heart disease, stroke and chronic non-neoplastic respiratory disease; plus deaths in childhood caused by SHS, deaths in adults from other conditions known to be caused by active smoking and the significant, serious morbidity, both acute and chronic, caused by SHS. Special Eurobarometer 385/2012 indicates that almost one third of European citizens currently smoke either cigarettes, cigars or a pipe. As smoking is responsible for half the difference in deaths across socio-economic groups, tobacco control has a major role to play in reducing health and social inequalities.ENSP plays a major role in Europe to prevent the tobacco industry from biaising and slowing down the tobacco control process. Indeed, ENSP was created for a tighter collaboration within the tobacco control community and for a stronger and united civil society action against tobacco. Key objectives during 2015-2017:- The support to the Directive 2014/40/EU and FCTC implementation- The facilitation of the creation and the operation of national alliances for tobacco control in Europe.- The stimulation of and the participation in European projects - The facilitation of networking in Europe- The collection and distribution of informationEuropean Network for Smoking and Tobacco Prevention 2015-2017: connecting, sharing, advocating to save lives!


The Correlation Network (CN) is a European civil society network and centre of expertise in the field of drug use, harm reduction and social inclusion.

Overall objective of this proposal:
Improve the access to and the quality of harm reduction services for People Who Use Drugs (PWUD), including other related vulnerable and marginalised people and to enhance policies and practices that increase social inclusion.

This is achieved by the following strategic objectives
- Strengthen the network and the collaboration with its members and partners through an adequate and solid organisational network structure
- Monitor developments and collect information and evidence in the field of drug use and harm reduction, by involving the expertise of civil society organisations
- Strengthen capacities of the various players in the field of drug use and harm reduction and facilitate exchange between network members and partners
- Advocate for full coverage of harm reduction programmes in Europe, addressing both health and social aspects.

All CN activities will pay specific attention to Hepatitis C, new drug trends and drug patterns and overdose prevention. Relevant CN outputs include : Sustainable network, Annual Monitoring Reports, Online knowledge and training hub, European Harm Reduction Conferences (2018/20), policy recommendations.

CN contributes to the Third Health Programme (THP) by promoting health (in particular harm reduction), prevent diseases (in particular drug-related diseases and infectious diseases such as HCV and HIV/AIDS), and foster supportive environments for healthy lifestyles (e.g. by reducing barriers to access health and social services).

CN contributes as well to the following THP priorities:
1.2. Drugs-related health damage, including information and prevention
1.3. HIV/AIDS, tuberculosis and hepatitis
2.2. Capacity-building against health threats in Member States, including, where appropriate, cooperation with
neighbouring countries



